Huons Global Co., Ltd. (084110.KQ)
KRW 43050.0
(-4.01%)
KRW 43050.0
(-4.01%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 407.28 Billion KRW | -10.92% |
| 2022 | 457.23 Billion KRW | 5.69% |
| 2021 | 432.62 Billion KRW | 47.34% |
| 2020 | 293.62 Billion KRW | 83.11% |
| 2019 | 160.35 Billion KRW | 19.45% |
| 2018 | 134.24 Billion KRW | 12.67% |
| 2017 | 119.14 Billion KRW | 15.5% |
| 2016 | 103.16 Billion KRW | 37.91% |
| 2015 | 74.8 Billion KRW | 13.1% |
| 2014 | 66.13 Billion KRW | -18.34% |
| 2013 | 80.98 Billion KRW | -12.54% |
| 2012 | 92.6 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 408.82 Billion KRW | 2.59% |
| 2024 Q1 | 398.5 Billion KRW | -2.16% |
| 2023 FY | 407.28 Billion KRW | -10.92% |
| 2023 Q3 | 393.6 Billion KRW | -0.02% |
| 2023 Q2 | 393.66 Billion KRW | -5.85% |
| 2023 Q1 | 418.09 Billion KRW | -8.56% |
| 2023 Q4 | 407.28 Billion KRW | 3.48% |
| 2022 Q4 | 457.23 Billion KRW | 4.24% |
| 2022 Q1 | 449.12 Billion KRW | 3.81% |
| 2022 Q2 | 455.24 Billion KRW | 1.36% |
| 2022 Q3 | 438.64 Billion KRW | -3.65% |
| 2022 FY | 457.23 Billion KRW | 5.69% |
| 2021 Q1 | 319.85 Billion KRW | 8.93% |
| 2021 Q2 | 367.59 Billion KRW | 14.93% |
| 2021 Q3 | 357.28 Billion KRW | -2.8% |
| 2021 Q4 | 432.62 Billion KRW | 21.09% |
| 2021 FY | 432.62 Billion KRW | 47.34% |
| 2020 FY | 293.62 Billion KRW | 83.11% |
| 2020 Q1 | 170.53 Billion KRW | 6.35% |
| 2020 Q3 | 253.16 Billion KRW | 0.02% |
| 2020 Q4 | 293.62 Billion KRW | 15.98% |
| 2020 Q2 | 253.1 Billion KRW | 48.42% |
| 2019 FY | 160.35 Billion KRW | 19.45% |
| 2019 Q2 | 145.16 Billion KRW | -8.49% |
| 2019 Q4 | 160.35 Billion KRW | 7.0% |
| 2019 Q1 | 158.63 Billion KRW | 18.17% |
| 2019 Q3 | 149.85 Billion KRW | 3.23% |
| 2018 Q2 | 115.61 Billion KRW | -8.42% |
| 2018 Q4 | 134.24 Billion KRW | 21.26% |
| 2018 Q3 | 110.7 Billion KRW | -4.25% |
| 2018 Q1 | 126.23 Billion KRW | 6.09% |
| 2018 FY | 134.24 Billion KRW | 12.67% |
| 2017 Q1 | 112.63 Billion KRW | 9.18% |
| 2017 Q2 | 109.48 Billion KRW | -2.8% |
| 2017 Q3 | 114.33 Billion KRW | 4.44% |
| 2017 FY | 119.14 Billion KRW | 15.5% |
| 2017 Q4 | 118.99 Billion KRW | 4.07% |
| 2016 Q1 | 665.36 Billion KRW | 789.5% |
| 2016 FY | 103.16 Billion KRW | 37.91% |
| 2016 Q4 | 103.16 Billion KRW | 1.75% |
| 2016 Q3 | 101.38 Billion KRW | 258.59% |
| 2016 Q2 | 28.27 Billion KRW | -95.75% |
| 2015 FY | 74.8 Billion KRW | 13.1% |
| 2015 Q4 | 74.8 Billion KRW | 0.66% |
| 2015 Q3 | 74.3 Billion KRW | 10.64% |
| 2015 Q2 | 67.16 Billion KRW | -6.11% |
| 2015 Q1 | 71.53 Billion KRW | 8.17% |
| 2014 Q1 | 81.17 Billion KRW | 0.23% |
| 2014 FY | 66.13 Billion KRW | -18.34% |
| 2014 Q3 | 67.06 Billion KRW | -3.29% |
| 2014 Q4 | 66.13 Billion KRW | -1.38% |
| 2014 Q2 | 69.34 Billion KRW | -14.57% |
| 2013 Q2 | 84.11 Billion KRW | -5.74% |
| 2013 Q1 | 89.24 Billion KRW | -3.63% |
| 2013 Q4 | 80.98 Billion KRW | -4.42% |
| 2013 Q3 | 84.73 Billion KRW | 0.74% |
| 2013 FY | 80.98 Billion KRW | -12.54% |
| 2012 FY | 92.6 Billion KRW | 0.0% |
| 2012 Q4 | 92.6 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 53.19 Billion KRW | -665.603% |
| CMG Pharmaceutical Co., Ltd. | 40.02 Billion KRW | -917.458% |
| Celltrion Pharm, Inc. | 264.97 Billion KRW | -53.706% |
| DongKook Pharmaceutical Co., Ltd. | 263.36 Billion KRW | -54.65% |
| Enzychem Lifesciences Corporation | 16.91 Billion KRW | -2307.296% |
| Humedix Co., Ltd. | 21.91 Billion KRW | -1758.516% |
| Boditech Med Inc. | 30.48 Billion KRW | -1236.019% |
| EuBiologics Co., Ltd. | 67.82 Billion KRW | -500.504% |
| FutureChem Co.,Ltd | 8.91 Billion KRW | -4466.61% |
| Huons Co., Ltd. | 206.87 Billion KRW | -96.878% |
| BNC Korea Co., Ltd. | 21.94 Billion KRW | -1755.867% |
| AptaBio Therapeutics Inc. | 38.19 Billion KRW | -966.423% |